Expression for both groups was reduced by PT2399 treatment in patient-derived xenografts in which PT2399 is effective at suppressing in vivo tumor growth, further supporting the idea that ARNT and BMAL1 promote the expression of overlapping and distinct sets of HIF2α target genes that are relevant for therapeutic responses to HIF2α antagonists in ccRCC. The gene discussed is ARNT; the disease is neoplasm.